Articles tagged with Breast Cancer Cells
Scientists found that high levels of insulin-like growth factor 1 receptor (IGF1R) expression are required for leukemia-initiating cell activity in T-cell acute lymphoblastic leukemia (T-ALL). Blocking IGF1R using inhibitors or reducing its expression significantly impaired leukemia stem cells' self-renewal capacity.
Researchers at the University of Houston discovered the potential for estrogen hormone compounds to prevent colon cancer by activating estrogen receptors. They also identified a key gene involved in breast cancer tumor cell growth, opening new opportunities for targeted therapeutics.
Researchers at Georgetown University Medical Center have identified a mutant gene STAG2 that is commonly mutated in human cancers and causes aneuploidy, an abnormal number of chromosomes. The study found that 20% of brain, skin, and bone cancer samples lacked the STAG2 protein, leading to increased risk of cancer.
Researchers at the Broad Institute and Whitehead Institute found that cancer cells can interconvert between different types, existing in phenotypic 'states' that can change over time. This decentralized model challenges the traditional view of cancer stem cells as a hierarchical society.
Abnormalities in breast cancer stem cells found in some cancers can lead to tumor development and recurrence, according to a recent study published by OHSU Knight Cancer Institute researchers. The study suggests that these mutated cells are resistant to chemotherapy and radiation, allowing the disease to recur.
A study in mice found that a genetic variation in the CDKAL1 gene leads to misreading of insulin-producing genes, causing decreased insulin production and impaired cell function. Meanwhile, researchers discovered that breast cancer cells evade the antitumor activity of NK cells by modifying their environment.
Researchers found that NSAIDs inhibit COX-2, reducing tumor growth and metastasis. However, the safety of these drugs during pregnancy remains uncertain due to the complex changes occurring in the body after childbirth.
Researchers present novel approaches to breast cancer treatment, including reconstituted cholesterol as a drug delivery model and heat-activated peptide therapy. These methods aim to improve patient outcomes by reducing side effects and increasing targeted treatments.
Scientists identify two genetic sequences that control how a breast cancer gene responds to estrogen, leading to tamoxifen resistance. The discovery may help guide the search for new therapeutic targets in breast cancer.
Scientists discovered a novel compound, piperlongumine, that selectively targets cancer cells' response to oxidative stress, inducing cell death without harming normal cells. The compound's effectiveness surpassed that of a commonly used chemotherapy drug, paclitaxel.
Scientists at Dana-Farber Cancer Institute have identified a novel subtype of breast cancer that grows in response to androgen but not estrogen. The study reveals the signaling pathways involved in its growth and demonstrates that drugs capable of blocking these pathways can inhibit tumor growth.
Using mice, researchers identified differences in viscoelastic properties between early and advanced stages of ovarian cancer. They found that benign cells are stiffer and more viscous than malignant cells, which is consistent with previous studies on other types of cancer.
A team of researchers at CSHL identified the PTPN23 enzyme as a significant regulator of breast cancer development. Suppressing its expression in human mammary cells led to a cascade of effects, including cell scattering, invasion through extracellular matrix, and metastasis.
A Johns Hopkins team discovered that cancer cells exhibit a universal 'chaotic' pattern of methylation, leading to unpredictable gene function and increased randomness. This finding may require a new approach to cancer therapy, focusing on helping cancer cells return to normal instead of just killing them.
A new roadmap has been published to understand estrogen signaling in breast cancer cells, which could lead to better treatments and therapies. The model aims to capture the molecular events controlling cell growth, proliferation, damage responses, and programmed cell death in mathematical form.
Breast cancer stem cells can be induced to transition into a mesenchymal and stem cell-like state by signals from breast epithelial cells. Blocking these autocrine signals inhibits the growth of tumors in animal models. The study suggests that targeting these signals could lead to effective treatment for breast cancer.
Researchers at Queen Mary University of London found that relocating Met molecules from the inside to the cell surface could halt cancer growth and shrink tumours. This approach may lead to new drugs for treating aggressive breast and lung cancers.
Researchers identified a key role for hedgehog in breast cancer cellular cross-talk, finding that silencing the molecule slows tumour growth and spread. The discovery applies to all breast cancers, particularly basal breast cancer, which has no current targeted therapy.
Researchers identified PKC-delta as a critical regulator of cisplatin-mediated kidney toxicity, and inhibiting it protected the kidneys without blocking chemotherapy efficacy in mouse models. Additionally, studies divided breast cancers into subtypes to identify effective therapies for triple-negative breast cancer patients.
Researchers at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors. The Jak2/Stat3 pathway was found to be elevated in these cells, and a drug specifically aimed at blocking this pathway halted tumor growth in mice.
A protein activated by diabetes drugs may slow cancer spread in breast tumors, and removing it increases cancer risk. Women exposed to environmental pollutants or poor diets are more likely to develop aggressive breast cancers.
Researchers discovered a new way breast cancer cells adapt to starvation conditions by turning to fatty acids for energy. This adaptation highlights the resilience of cancer cells and could lead to targeted therapies that block their ability to survive.
Researchers discovered that breast cancer cells can thrive under starvation conditions by using fatty acids as an alternative energy source. The protein CPT1C plays a key role in this adaptation, and its expression is increased under conditions of metabolic stress.
A UT Southwestern researcher has identified the most comprehensive measurement to date of estrogen's effect on breast cancer cells, showing that estrogen regulates a strikingly large percentage of all RNA molecules in a rapid and transient manner. This finding could lead to new therapeutic applications and provide a model for understan...
Researchers identified a regulatory protein that inhibits cancer cell spread by removing an invasive enzyme. This enzyme degrades surrounding tissues, facilitating cancer metastasis. The discovery may lead to more targeted therapies with specific inhibitory functions.
A study published in the Journal of the National Cancer Institute found that breast cancers discovered between screening mammograms tend to be more aggressive and have a poorer prognosis. The research compared data from women with interval cancers (detected between mammograms) to those detected during routine screening.
Researchers found that healthy breast cells secrete interleukin 25 to actively kill nearby breast cancer cells without harming normal cells. This discovery suggests IL25 receptor signaling as a new therapeutic target for treating breast cancer.
Whitehead Institute researchers found that differentiated cells in breast tissue can convert to a stem-cell-like state, challenging scientific dogma. This behavior may have implications for cancer therapeutics and degenerative disease therapy.
Researchers identified CRSBP-1 ligand molecules that bind to receptors on lymphatic vessels, gaining entry and facilitating cancer cell spread. This mechanism can be targeted to prevent metastases and treat edema, strengthening immune responses.
Fox Chase researchers identify retinoic acid as a promising therapy for early-stage breast cancer, inhibiting cell growth and proliferation. The study's findings suggest that the treatment may be effective in stopping tumor progression at its earliest stages.
The discovery of the SIRT3 protein's role in altering the nutrition of breast cancer cells has significant implications for cancer treatment. By identifying this protein as a 'guardian' of metabolism, researchers may develop targeted therapies to promote its activation and inhibit cancer growth.
Researchers found that breast cancer cells activate the unfolded protein response to evade anti-estrogen treatment, leading to increased resistance. Over-expression of XBP1 is a key driver of this process, suggesting a new target for restoring sensitivity to anti-estrogen therapies.
The American Association for Cancer Research (AACR) recognizes leaders in the minority cancer community with the Minority-Serving Institution Faculty Scholars in Cancer Research Awards. The awards aim to increase scientific knowledge, encourage research, and inspire students to pursue careers in cancer research.
The American Association for Cancer Research has awarded 50 Minority Scholar in Cancer Research Awards to early-career scientists from diverse backgrounds. The recipients, who were chosen based on their qualifications and potential impact, will receive funding and support to attend the annual meeting and present their research.
Researchers discover PinX1's role in preventing chromosome instability and cancer initiation. Low levels of PinX1 contribute to cancer development by activating telomerase, a process linked to human cancers with genetic alterations at chromosome 8p23.
A new synchrotron-based imaging technique provides high-resolution pictures of tissue molecular composition with unprecedented speed and quality. The IRENI facility cuts imaging time from hours to minutes while quadrupling sample size range, revealing detailed structure and chemistry.
Measuring mechanical strength of cancer cell mucus layers provides clues about treating cancer. Cancer cells produce excessive mucus, forming a barrier that prevents drugs from reaching them.
Researchers discovered that human mammary epithelial cells possess lineage-specific intrinsic abilities to self-organize into domains of lineage specificity, maintaining healthy bi-layered branching organization. The study provides insights into the coordination of stem cell differentiation and tissue architecture maintenance.
A UCSF team has developed a new model for how inherited genes contribute to frontotemporal lobar degeneration, a neurodegenerative disease. The study suggests that progranulin regulates the speed of dying cells being cleared from the brain.
Researchers have shown how laminin influences genetic information inside a cell's nucleus, while its destruction plays a detrimental role in tumor development. The study also identifies laminin-111 as the regulator of nuclear actin, a key mediator of epithelial cell quiescence.
A Australian researcher has been awarded a $4 million fellowship to continue her work on the origin of breast, ovarian and lung cancers. The research aims to understand the basic biology of epithelial organs and identify molecular pathways that go awry in these cancers.
Scientists at Queen's University Belfast have developed a gene delivery system that targets and kills breast cancer cells using an innovative nanoparticle transport system. The iNOS gene forces cancer cells to produce poisonous nitric oxide, leading to cell death or increased vulnerability to chemotherapy and radiotherapy.
Researchers at Penn State College of Medicine have developed cerasomes, molecular-sized bubbles filled with chemotherapy drugs, to treat liver cancer. These tiny bubbles target cancer cells specifically and accurately, avoiding healthy cells.
A newly discovered biological pathway transforms normal cells into aggressive tumors by regulating the epithelial-mesenchymal transition (EMT) process. This mechanism involves a specific molecular factor called hnRNP E1, which can be used as a diagnostic approach for cancer.
A recent study found that reprogramming stem cells leads to genomic aberrations and genetic mutations similar to those in cancer cells. This raises concerns about the safety and effectiveness of using these cells for regenerative medicine applications.
Researchers at UT MD Anderson Cancer Center discovered that overproduction of the EZH2 protein promotes growth of breast cancer stem cells. The team also identified two drugs that block the molecular events leading to breast tumor-initiating cell formation, which drives cancer progression.
Researchers found that oestrogen can reduce the proportion of breast cancer stem cells, explaining a better prognosis for tumours expressing the oestrogen receptor. This study presents new insights into oestrogen's effect on cancer stem cells and opens doors to developing tools for preventing breast cancer.
A new study reveals that BRCA1 mutations regulate cell fate in breast tissue, leading to the formation of aggressive basal-like tumors. Cells with mutant BRCA1 exhibit elevated Slug levels and remain immature, stalled in a premature state of development.
Researchers discovered that breast cancer cells release heat shock protein 27 (Hsp27), which renders immune cells unresponsive and fuels tumor growth. This finding provides a new treatment target in the fight against breast cancer.
Magnetic nanoparticles can detect cervical cancer by trapping antibodies, offering earlier screening and treatment. Similarly, these nanoparticles can detect E. coli infections at lower bacterial cell counts, halting disease spread faster.
Scientists discovered that broccoli's cancer-fighting compounds target the p53 gene, which is often mutated in human cancers. Isothiocyanates from broccoli may remove the defective protein, leaving normal cells intact, paving the way for new cancer treatments.
Researchers at the University of Nottingham successfully reactivated tumour suppressor genes in breast cancer cells by treating them with Axolotl oocyte extract, stopping cancerous growth after 60 days. This breakthrough discovery holds promise for developing a powerful new technology platform for the treatment of various cancers.
Researchers at Virginia Tech have developed a new method to detect the ability of breast cancer cells to metastasize, using specific silicon microdevices. The technology has the potential to provide important diagnostic and prognostic markers unique to the tumor.
High expression of TRIM24 in breast cancer correlates with poor survival, as it disables tumor suppressor p53 and stimulates estrogen receptor activity. The study suggests that TRIM24 could be a therapeutic target to prevent breast tumorigenesis.
Researchers at Kimmel Cancer Center have found that breast inflammation promotes the development and progression of breast cancer. By selectively blocking inflammation in the breast, they were able to prevent tumor formation and reduce cancer stem cells.
Researchers found that CTCs in blood before chemotherapy and after transplant are associated with reduced survival and faster recurrence. The study adds insights into how hematopoietic progenitor cells recruit CTCs from bone marrow, which may be responsible for cancer recurrence.
Researchers discovered TXNL2 helps protect human breast cancer cells from high levels of reactive oxygen species (ROS), which can contribute to tumor development and progression. Enhanced TXNL2 expression correlated with cancer spread and decreased survival rates in primary breast cancer samples.
Researchers at the University of Illinois developed a new microscopy technique that can identify cancer cells with over 99% confidence in under five minutes. The technique uses nonlinear interferometric vibrational imaging to analyze molecular composition and produce color-coded images, providing clear tumor boundaries.
A study published in Cancer Research reveals that microRNA-375 plays a crucial role in breast cancer cells, leading to increased estrogen receptor alpha levels. Blocking this microRNA effectively slows down cancer cell growth, offering potential new strategies for treatment.
Researchers at the University of Georgia have discovered a key enzyme that regulates the early growth of breast cancer cells, which can delay tumor onset and spread by blocking GnT-V activity. The study found that eliminating this enzyme reduces breast cancer stem cells, potentially leading to new drug targets and treatment options.